^
Association details:
| Biomarker: | NRG1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | patritumab (U3-1287) (HER3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
Excerpt:
The subgroup of patients with high HRG mRNA levels (“HRG-high”) demonstrated clinical benefit from patritumab treatment with HRs of 0.37 (P = 0.0283) and 0.29 (P = 0.0027) in the high- and low-dose patritumab arms, respectively. However, only 102 of the 215 randomized patients (47.4%) had sufficient tumor samples for HRG mRNA measurement.
DOI:
10.1016/j.ebiom.2015.02.005
Trial ID:
